David G. Standaert

Active 1984–2025

171
Papers
28,292
Citations
98
h-index
164
i10-index

Citations

Citations per year for David G. Standaert1930: 1 citations1983: 1 citations1984: 2 citations1985: 13 citations1986: 45 citations1987: 31 citations1988: 63 citations1989: 35 citations1990: 24 citations1991: 26 citations1992: 28 citations1993: 12 citations1994: 20 citations1995: 40 citations1996: 49 citations1997: 55 citations1998: 55 citations1999: 70 citations2000: 108 citations2001: 112 citations2002: 109 citations2003: 182 citations2004: 201 citations2005: 182 citations2006: 200 citations2007: 167 citations2008: 206 citations2009: 187 citations2010: 257 citations2011: 255 citations2012: 214 citations2013: 228 citations2014: 271 citations2015: 285 citations2016: 250 citations2017: 282 citations2018: 318 citations2019: 820 citations2020: 952 citations2021: 1,019 citations2022: 898 citations2023: 733 citations2024: 1,107 citations2025: 623 citations2026: 39 citations1931–1982: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,754 citing papers, 28.8% of this breakdownChina: 1,072 citing papers, 8.2% of this breakdownUnited Kingdom: 953 citing papers, 7.3% of this breakdownItaly: 809 citing papers, 6.2% of this breakdownGermany: 765 citing papers, 5.9% of this breakdownCanada: 554 citing papers, 4.3% of this breakdownFrance: 405 citing papers, 3.1% of this breakdownSpain: 390 citing papers, 3% of this breakdownJapan: 288 citing papers, 2.2% of this breakdownSweden: 286 citing papers, 2.2% of this breakdownAustralia: 279 citing papers, 2.1% of this breakdownIndia: 277 citing papers, 2.1% of this breakdown
0%28.8%Other 24.6%

Fields

  • Medicine50.7%
  • Neuroscience26.6%
  • Biochemistry, Genetics and Molecular Biology15.1%
  • Computer Science2.6%
  • Engineering1.2%
  • Immunology and Microbiology0.9%
  • Other2.9%

Topics

  • Parkinson's Disease Mechanisms and Treatments14.1%
  • Neurological disorders and treatments7.4%
  • Neuroscience and Neuropharmacology Research4.9%
  • Neuroinflammation and Neurodegeneration Mechanisms4.2%
  • Genetic Neurodegenerative Diseases2.9%
  • Alzheimer's disease research and treatments2.7%
  • Other63.8%

Coauthors

All papers

Open in search
  1. The Parkinson Progression Marker Initiative (PPMI)

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Keith A. Hawkins, Jamie L. Eberling, Deborah W. Brooks, David Russell, Laura Leary, Stewart A. Factor, Barbara Sommerfeld, Penelope Hogarth, Emily Pighetti, Karen Williams, David G. Standaert, Stephanie Guthrie, Robert A. Hauser, Holly Delgado, Joseph Jankovic, Christine Hunter, Matthew Stern, Baochan Tran, Jim Leverenz, Marne Baca, Sam Frank, Cathi-Ann Thomas, Irene Hegeman Richard, Cheryl Deeley, Linda Rees, Fabienne Sprenger, Elisabeth Lang, Holly A. Shill, Sanja Obradov, Hubert Fernandez, Adrienna Winters, Daniela Berg, Katharina Gauss, Douglas Galasko, Deborah Fontaine, Zoltán Mari, Melissa Gerstenhaber, David J. Brooks, Sophie Malloy, Paolo Barone, Katia Longo, Tom Comery, Bernard Ravina, Igor D. Grachev, Kim P. Gallagher, Michelle Collins, Katherine L. Widnell, Suzanne Ostrowizki, Paulo Fontoura, Tony W. Ho, Johan Luthman, Marcel van der Brug, Alastair D. Reith, Peggy Taylor - Progress in Neurobiology 2011 cited by 1,915

  2. α-Synuclein-specific T cell reactivity is associated with preclinical and early Parkinson’s disease

    Authors: , , , , , , , , , , , , , , , , - Nature Communications 2020 cited by 393

  3. CD4 T cells mediate brain inflammation and neurodegeneration in a mouse model of Parkinson's disease

    Authors: , , , , , - Brain 2021 cited by 315

  4. Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Kenneth Marek, David G. Standaert, D. James Surmeier, C. Warren Olanow, Jeffrey H. Kordower, Paolo Calabresi, Anthony H.V. Schapira, A. Jon Stoessl - Movement Disorders 2017 cited by 845

  5. Border-associated macrophages mediate the neuroinflammatory response in an alpha-synuclein model of Parkinson disease

    Authors: , , , , , , , , , - Nature Communications 2023 cited by 139

  6. Identification of genetic risk loci and causal insights associated with Parkinson's disease in African and African admixed populations: a genome-wide association study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Kimberley J. Billingsley, Frank Imarhiagbe, Pilar Álvarez Jerez, Emmanuel Iwuozo, Breeana Baker, Morenikeji Komolafe, Laksh Malik, Paul Nwani, Kensuke Daida, Ernest Nwazor, Abigail Miano‐Burkhardt, Yakub Nyandaiti, Zih‐Hua Fang, Yahaya Obiabo, Jillian H. Kluss, Olanike Odeniyi, Dena Hernández, Francis Odiase, Nahid Tayebi, FI Ojini, Ellen Sidranksy, Gerald Onwuegbuzie, Andrea D'Souza, Godwin Osaigbovo, Bahafta Berhe, Nosakhare Osemwegie, Xylena Reed, Olajumoke Oshinaike, Hampton L. Leonard, Folajimi Otubogun, Chelsea X. Alvarado, Shyngle Oyakhire, Simon Ozomma, Sarah Samuel, Funmilola Tolulope Taiwo, Kolawole Wasiu Wahab, Yusuf Zubair, Hirotaka Iwaki, Jonggeol Jeffrey Kim, Huw R. Morris, John Hardy, Mike A. Nalls, Karl Heilbron, Lucy Norcliffe‐Kaufmann, Njideka Okubadejo, Oluwadamilola O. Ojo, Oluwadamilola Ojo, Charles Achoru, Osigwe Agabi, Uchechi Agulanna, Rufus Akinyemi, Mohammed Ali, Mohammed Ali, Ohwotemu Arigbodi, Abiodun Bello, Cyril Erameh, Temitope Farombi, Temitope Farombi, Frank Imarhiagbe, Emmanuel Iwuozo, Morenikeji Komolafe, Paul Nwani, Paul Nwani, Yakub Nyandaiti, Yahaya Obiabo, Olanike Odeniyi, Francis Odiase, FI Ojini, Gerald Onwuegbuzie, Godwin Osaigbovo and 354 more - The Lancet Neurology 2023 cited by 153

  7. Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , - The Lancet Neurology 2022 cited by 204

  8. Inhibition of the JAK/STAT Pathway Protects Against α-Synuclein-Induced Neuroinflammation and Dopaminergic Neurodegeneration

    Authors: , , , , , , , , , , , - Journal of Neuroscience 2016 cited by 275

  9. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study

    Authors: , , , , , , , , , , , , , , - The Lancet Neurology 2013 cited by 696

  10. Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson’s Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study

    Authors: , , , , , , , , , , , , , , , , , , , , , - Neurology and Therapy 2023 cited by 117

  11. MHCII Is Required for -Synuclein-Induced Activation of Microglia, CD4 T Cell Proliferation, and Dopaminergic Neurodegeneration

    Authors: , , , , , , , , , - Journal of Neuroscience 2013 cited by 427

  12. LRRK2 Inhibition Attenuates Microglial Inflammatory Responses

    Authors: , , , , , , , - Journal of Neuroscience 2012 cited by 476

  13. Ser(P)‐1292 LRRK2 in urinary exosomes is elevated in idiopathic Parkinson's disease

    Authors: , , , , , , - Movement Disorders 2016 cited by 210

  14. CD4+ Regulatory and Effector/Memory T Cell Subsets Profile Motor Dysfunction in Parkinson’s Disease

    Authors: , , , , , , , , , , , , , - Journal of Neuroimmune Pharmacology 2012 cited by 324

  15. Peripheral monocyte entry is required for alpha-Synuclein induced inflammation and Neurodegeneration in a model of Parkinson disease

    Authors: , , , , , , , , , - Experimental Neurology 2017 cited by 240

  16. Monitoring Motor Fluctuations in Patients With Parkinson's Disease Using Wearable Sensors

    Authors: , , , , , , , , , - IEEE Transactions on Information Technology in Biomedicine, IEEE Trans. Inf. Technol. Biomed. 2009 cited by 620

  17. Dysregulation of the Adaptive Immune System in Patients With Early-Stage Parkinson Disease

    Authors: , , , , , , , - Neurology Neuroimmunology & Neuroinflammation 2021 cited by 118

  18. Brain and Systemic Inflammation in De Novo Parkinson's Disease

    Authors: , , , , , , , , , , , , , - Movement Disorders 2023 cited by 62

  19. Targeted Overexpression of Human α-Synuclein Triggers Microglial Activation and an Adaptive Immune Response in a Mouse Model of Parkinson Disease

    Authors: , , , - Journal of Neuropathology & Experimental Neurology 2008 cited by 368

  20. Role of α-Synuclein in Inducing Innate and Adaptive Immunity in Parkinson Disease

    Authors: , - Journal of Parkinson s Disease 2015 cited by 241

  21. Ten Unsolved Questions About Neuroinflammation in Parkinson's Disease

    Authors: , - Movement Disorders 2020 cited by 190

  22. microRNA-155 Regulates Alpha-Synuclein-Induced Inflammatory Responses in Models of Parkinson Disease

    Authors: , , , - Journal of Neuroscience 2016 cited by 241

  23. Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - Neurology 2019 cited by 267

  24. Biomarker‐driven phenotyping in Parkinson's disease: A translational missing link in disease‐modifying clinical trials

    Authors: , , , , , , , , , , , , , , , - Movement Disorders 2017 cited by 183